Vemurafenib combined with cytarabine and cladribine results in clinical efficacy but persistent BRAF^V600E clone in a newborn affected by high-risk Langerhans cell histiocytosis.

IF 5.1 2区医学 Q1 HEMATOLOGY

British Journal of Haematology Pub Date : 2024-07-10 DOI:10.1111/bjh.19637

Linda Beneforti, Aurora Chinnici, Maria Luisa Coniglio, Maria Rosaria Papa, Liana Punzi, Elena Sieni, Carmela De Fusco

引用次数: 0

查看原文本刊更多论文

维莫非尼与阿糖胞苷和克拉德宾联合治疗高危朗格汉斯细胞组织细胞增生症的新生儿，临床疗效显著，但BRAFV600E克隆持续存在。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Haematology 医学-血液学

CiteScore

8.60

自引率

4.60%

发文量

565

审稿时长

1 months

期刊介绍： The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

文献相关原料

公司名称	产品信息	采购帮参考价格

Vemurafenib combined with cytarabine and cladribine results in clinical efficacy but persistent BRAFV600E clone in a newborn affected by high-risk Langerhans cell histiocytosis.

Vemurafenib combined with cytarabine and cladribine results in clinical efficacy but persistent BRAF^V600E clone in a newborn affected by high-risk Langerhans cell histiocytosis.